France-based Aglaia raises seed funding

Thursday 30 September 2021


Aglaia Therapeutics SAS, a French start-up company, has raised €4 million in seed financing to start preclinical development of cancer drugs that can overcome a patient’s resistance to current targeted therapies. The company’s portfolio is based on research showing that the abnormal activation of the eIF4F protein complex leads to the synthesis of proteins involved in tumour growth.